Videos

The director of Integrative Neurosciences at Allegheny Health Network talked about integrative neurology, personalized medicine, and emerging diagnostic tools that enhance patient-centered care. [WATCH TIME: 5 minutes]

The chair of neurosurgery at the University of Arizona talked about the newly approved infusion therapy that offers continuous medication delivery to improve both motor and non-motor symptoms in Parkinson disease. [WATCH TIME: 5 minutes]

The clinical researcher at St. Jude Children's Research Hospital discussed the evolving treatment landscape for Charcot-Marie-Tooth disease, which will be featured in a session at the 2025 MDA Conference. [WATCH TIME: 7 minutes]

The president and CEO at Project Sleep highlighted the need for clinicians to facilitate awareness of patient advocacy resources for those living with narcolepsy or idiopathic hypersomnia. [WATCH TIME: 5 minutes]

Panelist discusses how the neuroanatomy of bladder function involves a sophisticated interplay between autonomic and somatic nervous systems. The bladder is controlled by parasympathetic nerves (S2-S4) for detrusor contraction, sympathetic nerves (T11-L2) for sphincter control, and somatic nerves for voluntary control via the pudendal nerve. This complex coordination enables both automatic storage and voluntary voiding through reciprocal innervation.

The director of the Cerebrovascular Center at Mount Sinai talked about findings from recent trials presented at ISC 2025 investigating thrombectomy for distal vessel occlusions. [WATCH TIME: 4 minutes]

The director of the Parkinson’s Disease and Movement Disorders Center of Boca Raton, Florida, commented on the promising safety of SPN-830 and who may be best suited for treatment with the newly approved therapy. [WATCH TIME: 4 minutes]

The professor and chair of the neurology department at the University of Arizonia, Phoenix, gave clinical insights on the notable progress in the stroke treatment world, highlighted by advances presented at the 2025 International Stroke Conference. [WATCH TIME: 3 minutes]

The professor at the Second Affiliated Hospital of Zhejiang University’s School of Medicine discussed findings from a trial suggesting that intravenous thrombolysis could benefit patients with ischemic stroke up to 24 hours after symptom onset. [WATCH TIME: 8 minutes]

The director of the neurological disease center at Beijing Anzhen Hospital talked about assessing the potential benefits and safety of intra-arterial tenecteplase in highly selected poststroke patients. [WATCH TIME: 6 minutes]

Neurology News Network. for the week ending February 9, 2025. [WATCH TIME: 4 minutes]

The movement disorders nurse practitioner at The Ohio State University Wexner Medical Center talked about a meeting that equips nurse practitioners and physician assistants to improve movement disorder patient care. [WATCH TIME: 5 minutes]

The director of the Parkinson’s Disease and Movement Disorders Center of Boca Roaton, Florida, gave clinical insight on the function of a newly approved therapy for Parkinson disease, a common neurodegenerative disorder. [WATCH TIME: 3 minutes]

The group of women neurologists provided commentary on the critical areas of women-focused research in neurology, from clinical trial participation to addressing workforce challenges.

Panelists explore the challenges and opportunities for women in neurology, offering practical advice for young professionals navigating the field.

The president and CEO at Project Sleep talked about the foundational role of social connections and peer support in improving quality of life for individuals with narcolepsy. [WATCH TIME: 5 minutes]

The director of the Parkinson’s Disease and Movement Disorders Center of Boca Raton, Florida, discussed SPN-830, the first and only FDA-approved subcutaneous apomorphine infusion device for patients with Parkinson disease. [WATCH TIME: 2 minutes]

The professor of neurology at the Geisel School of Medicine at Dartmouth shared his reaction to the recent FDA approval of AXS-07, a combination of meloxicam and rizatriptan, as a new therapy for acute migraine management. [WATCH TIME: 4 minutes]

In this episode, women neurologists share their personal experiences navigating challenges in neurology, offering insights into mentorship, work-life balance, and career advancement.

The director of the Montefiore Headache Center at Albert Einstein College of Medicine discussed the recent FDA approval of a new migraine treatment that combines rizatriptan and meloxicam. [WATCH TIME: 5 minutes]

A group of empowering women leaders in neurology explore the transformative impact of women neurologists on the medical workforce and the strides toward a more inclusive neurology field.

A group of empowering women leaders in neurology explore the transformative impact of women neurologists on the medical workforce and the strides toward a more inclusive neurology field.

The chair of psychiatry at Tufts University School of Medicine discussed ongoing research exploring the potential of cannabinoids in treating agitation in Alzheimer disease. [WATCH TIME: 5 minutes]

Neurology News Network. for the week ending February 2, 2025. [WATCH TIME: 4 minutes]

The medical director of the Arkansas Children’s Comprehensive Epilepsy Program detailed advancements and strategies in using neuromodulation for LGS, as well as the future research needed to expand these approaches. [WATCH TIME: 4 minutes]

The chief medical advisor at the Muscular Dystrophy Association shared key highlights of what attendees can expect at the 2025 MDA Clinical and Scientific Conference. [WATCH TIME: 4 minutes]

The chief of neuroinfectious diseases and global neurology at Northwestern Medicine talked about a relatively new autoimmune condition, marked by mitochondrial dysfunction. [WATCH TIME: 2 minutes]

The William S. and Lois Stiles Edgerly Professor of Neurology at Yale School of Medicine talked about refining multiple sclerosis in line with the updated diagnostic criteria. [WATCH TIME: 5 minutes]